REG - Feedback PLC - Result of AGM & Proposed Share Consolidation

FeedbackAnnouncement

13/10/2022 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221013:nRSM8407Ca&default-theme=true

RNS Number : 8407C  Feedback PLC  13 October 2022

Feedback plc

 

Result of AGM & Proposed Share Consolidation

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical
imaging technology company, announces that at the Annual General Meeting
("AGM") held today all resolutions were duly passed.

 

The results of the poll (including proxy votes on the resolutions) are
included below.

 

 Resolutions                                                                     Votes For**    % of votes cast***  Votes Against  % of votes cast***  Votes Withheld***  Total votes cast***
 1)   To receive and adopt the Company's annual accounts for the year ended      1,435,070,825  100.00              0              0.00                1,636,537          1,435,070,825
 31 May 2022 together with the Directors' report and the Auditors' report
 thereon
 2)   To receive and approve the report on Directors' remuneration for the       666,547,017    57.85               485,714,290    42.15               83,017,483         1,152,261,307
 year ended 31 May 2022
 3)   To re-appoint Price Bailey LLP as Auditor of the Company                   1,300,785,111  100.00              0              0.00                1,636,537          1,300,785,111
 4)   To authorise the Directors to determine the fees payable to the Auditor    1,435,070,825  100.00              0              0.00                1,636,537          1,435,070,825
 5)   To elect Anesh Patel as a Director of the Company                          1,435,037,825  100.00              33,000         0.00                1,636,537          1,435,070,825
 6)   To elect Annemijn Eschauzier as a Director of the Company                  1,435,037,825  100.00              33,000         0.00                1,636,537          1,435,070,825
 7)   To re-elect Rory Shaw as a Director of the Company                         949,356,535    100.00              0              0.00                487,350,827        949,356,535
 Special Business
 8)   That the Directors be and are hereby generally and unconditionally         1,388,179,455  96.73               46,891,370     3.27                1,636,537          1,435,070,825
 authorised to allot relevant securities pursuant to section 551 of the
 Companies Act 2006
 Special Resolution                                                              1,388,596,455  96.76               46,474,370     3.24                1,636,537          1,435,070,825

 9)   To resolve that the Directors be empowered to allot equity securities
 for cash and/or to sell equity securities held as treasury shares for cash

 10)  That every 200 ordinary shares of £0.0025 each in the capital of the       1,376,208,959  95.90               58,861,866     4.10                1,636,537          1,435,070,825
 Company are hereby consolidated into one ordinary share of £0.50
 Special resolution                                                              1,376,208,959  95.90               58,861,866     4.10                1,636,537

 11)  That, the Articles be amended by the insertion of a new article 2.5

                                                                                                                                                                          1,435,070,825

 

 

 

Notes:

* "Votes For" include votes giving the Chairman discretion.

** Percentages exclude "Votes Withheld".

*** "Votes Withheld" are not votes in law and do not count in the number of
votes counted for or against a resolution.

**** "Total votes cast" do not include withheld votes.

Share Consolidation

Following the approval of the Consolidation Resolution (resolution 10 above),
every 200 ordinary shares of £0.0025 each (the "Existing Shares") that are in
issue as at 6.00 p.m. today will be consolidated into one new ordinary share
of £0.50 each (the "New Ordinary Shares"). Other than the change in nominal
value, the New Ordinary Shares arising on implementation of the Share
Consolidation will have the same rights as the Existing Ordinary Shares,
including voting and other rights.

 

The New Ordinary Shares arising from the Share Consolidation will be admitted
to trading on AIM from 8.00 a.m. on 14 October 2022 ("Admission") with ISIN
number GB00BJN59X09 and SEDOL code BJN59X0.

 

Total Voting Rights

Following Admission, the Company's issued share capital will
comprise 13,334,659 New Ordinary Shares with voting rights. This figure
of 13,334,659 New Ordinary Shares may be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change in their interest in,
the share capital of the Company under the Disclosure Rules and Transparency
Rules of the United Kingdom Financial Conduct Authority.

 

Save as defined herein, capitalised terms have the same meaning as in the
Company's notice of AGM which is available on the Company's website.

 

-Ends-

 

Enquiries:

 

 Feedback plc                                    +44 (0) 20 3997 7634

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                                Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome                          07980 541 893 or 07748 325 236 or 07884 664 686

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for
patients. We design products that enhance clinician access to patient data and
to their colleagues. Our unique approach centres around individual patient
episodes, into which we pull relevant clinical data from hospital systems and
around which we build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available to
clinicians in multiple settings, in a format that enables them to meaningfully
interact with it, providing flexibility to clinicians and free movement of
patients between provider settings - clinicians can practice from anywhere and
patients can attend any care provider for treatment.

 

Our products Bleepa and CareLocker work together to deliver unparalleled value
to our customers. Bleepa is our application layer and sits on top of
CareLocker as our data layer. Bleepa is a clinician facing platform that
displays clinical results from a patient's CareLocker at a certified and
regulated quality, that is suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure, auditable chat
interface that links back to the patient medical record. The CareLocker data
storage model is built around the patient. Our vision is one where relevant
clinical data is always available to the patient as well as to any care
setting that they may attend -  a federated data architecture with the
patient as the tenant.

 

The Company has a number of growth opportunities domestically and
internationally across a range of markets including the NHS, the veterinary
market and private healthcare providers and its highly scalable Software as a
Service ("SaaS")-based revenue model is expected to provide increasing levels
of visibility as the Company grows its customer base.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGKZMMGFFZGZZM